Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study

European Neuropsychopharmacology

Volumn 18, Issue 3, 2008, Pages 170-180

  Bitter, Istvan ^a   Treuer, Tamas ^b   Dyachkova, Yulia ^b   Martenyi, Ferenc ^b   McBride, Margaret ^c   Ungvari, Gabor S ^d  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Eli Lilly Regional GmbH   (Austria)

^c ELI LILLY AUSTRALIA PTY LTD   (Australia)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antipsychotic agents; Drug; Prescription patterns; Schizophrenia; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ALGERIA; ARGENTINA; ARTICLE; CHILE; CLINICAL PRACTICE; CLINICAL TRIAL; COLOMBIA; COSTA RICA; CZECH REPUBLIC; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EGYPT; EL SALVADOR; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GUATEMALA; HONDURAS; HUMAN; HUNGARY; ISRAEL; LITHUANIA; MALAYSIA; MALE; MEXICO; MOTOR DYSFUNCTION; MULTICENTER STUDY; OBSERVATIONAL METHOD; OUTCOMES RESEARCH; OUTPATIENT; PATIENT COMPLIANCE; PERU; POLAND; POLYPHARMACY; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; PUERTO RICO; RISK FACTOR; ROMANIA; RUSSIAN FEDERATION; SAUDI ARABIA; SIDE EFFECT; SLOVAKIA; SLOVENIA; SOUTH KOREA; TAIWAN; TURKEY (REPUBLIC); VENEZUELA; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; ODDS RATIO; OUTPATIENTS; PREDICTIVE VALUE OF TESTS; PRESCRIPTIONS, DRUG; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME;

EID: 38149100275     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.08.001     Document Type: Article

References (34)

1. American Psychiatric Association. DSM-IV. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Association, Washington
2. Bitter I., Dossenbach M.R., Brook S., Feldman P.D., Metcalfe S., Gagiano C.A., Furedi J., Bartko G., Janka Z., Banki C.M., Kovacs G., and Breier A. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28 (2004) 173-180
3. Casey D.E., Daniel D.G., Wassef A.A., Tracy K.A., Wozniak P., and Sommerville K.W. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28 (2003) 182-192
4. Citrome L., Jaffe A., Levine J., and Allingham B. Use of mood stabilizers among patients with schizophrenia, 1994-2001. Psychiatr. Serv. 53 (2002) 1212
5. Citrome L., Jaffe A., Levine J., and Lindenmayer J.P. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J. Clin. Psychiatry 66 (2005) 1512-1516
6. Covell N.H., Jackson C.T., Evans A.C., and Essock S.M. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr. Bull. 28 (2002) 17-29
7. Davis J.M., Marder S.R., and Tamminga C.A. Switch or stay?. Am. J. Psychiatry 163 (2006) 2032-2033
8. Dossenbach M., Erol A., el Mahfoud K.M., Shaheen M.O., Sunbol M.M., Boland J., Hodge A., O'Halloran R.A., and Bitter I. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J. Clin. Psychiatry 65 (2004) 312-321
9. Edlinger M., Baumgartner S., Eltanaihi-Furtmuller N., Hummer M., and Fleischhacker W.W. Switching between second-generation antipsychotics: why and how?. CNS Drugs 19 (2005) 27-42
10. Edlinger M., Hausmann A., Kemmler G., Kurz M., Kurzthaler I., Walch T., Walpoth M., and Fleischhacker W.W. Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr. Res. 77 (2005) 25-34
11. Essock S.M., Covell N.H., Davis S.M., Stroup T.S., Rosenheck R.A., and Lieberman J.A. Effectiveness of switching antipsychotic medications. Am. J. Psychiatry 163 (2006) 2090-2095
12. Faries D., Ascher-Svanum H., Zhu B., Correll C., and Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5 (2005) 26
13. Fleischhacker W.W., Hummer M., Kurz M., Kurzthaler I., Lieberman J.A., Pollack S., Safferman A.Z., and Kane J.M. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J. Clin. Psychiatry 55 Suppl B (1994) 78-81
14. Gaebel W., Weinmann S., Sartorius N., Rutz W., and McIntyre J.S. Schizophrenia practice guidelines: international survey and comparison. Br. J. Psychiatry 187 (2005) 248-255
15. Ganguly R., Kotzan J.A., Miller L.S., Kennedy K., and Martin B.C. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J. Clin. Psychiatry 65 (2004) 1377-1388
16. Glick I.D., Pham D., and Davis J.M. Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. J. Clin. Psychiatry 67 (2006) 1261-1265
17. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J. Psychopharmacol., Suppl. 19 (2005) 16-27
18. Haro J.M., Edgell E.T., Jones P.B., Alonso J., Gavart S., Gregor K.J., Wright P., and Knapp M. The European Schizophrenia Outpatient Health Outcome (SOHO) study: rationale, methods and recruitment. Acta Psychiatr. Scand. 107 (2003) 222-232
19. Haro J.M., Kamath S.A., Ochoa S., Novick D., Rele K., Fargas A., Rodriguez M.J., Rele R., Orta J., Kharbeng A., Araya S., Gervin M., Alonso J., Mavreas V., Lavrentzou E., Liontos N., Gregor K., and Jones P.B. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr. Scand., Suppl. 416 (2003) 16-23
20. Ito H., Koyama A., and Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br. J. Psychiatry 187 (2005) 243-247
21. Kohn R., Saxena S., Levav I., and Saraceno B. The treatment gap in mental health care. Bull. World Health Organ. 82 (2004) 858-866
22. Lehman A.F., Buchanan R.W., Dickerson F.B., Dixon L.B., Goldberg R., Green-Paden L., and Kreyenbuhl J. Evidence-based treatment for schizophrenia. Psychiatr. Clin. North Am. 26 (2003) 939-954
23. Leslie D.L., and Rosenheck R.A. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am. J. Psychiatry 159 (2002) 1534-1540
24. Leucht S., Barnes T.R., Kissling W., Engel R.R., Correll C., and Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am. J. Psychiatry 160 (2003) 1209-1222
25. Lieberman J.A. Neurobiology and the natural history of schizophrenia. J. Clin. Psychiatry 67 (2006) 14
26. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
27. National Institute of Clinical Excellence. Schizophrenia: Full National Clinical Guideline on Core Interventions in Primary and Secondary Care (2003), Gaskell and the British Psychological Society, London
28. National Institute of Mental Health. Clinical Global Impressions (CGI). In: Guy W. (Ed). ECDEU Assessment Manual for Psychopharmacology (1976), US Department of Health Education, and Welfare, Bethesda 217-222
29. Sachs G.S., and Guille C. Weight gain associated with use of psychotropic medications. J. Clin. Psychiatry Suppl. 60 (1999) 16-19
30. Schooler N.R. Relapse and rehospitalization: Comparing oral and depot antipsychotics. J. Clin. Psychiatry 64 Suppl 16 (2003) 14-17
31. Sim K., Su A., Fujii S., Yang S.Y., Chong M.Y., Ungvari G.S., Si T., Chung E.K., Tsang H.Y., Chan Y.H., Heckers S., Shinfuku N., and Tan C.H. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br. J. Clin. Pharmacol. 58 (2004) 178-183
32. U.S. Food and Drug Administration. Report to Congress-Reports on Postmarketing Studies (2003). http://www.fda.gov/cber/fdama/pstmrktfdama130.htm Available at: http://www.fda.gov/cber/fdama/pstmrktfdama130.htm. Accessed September 20, 2003
33. Weiden P.J., and Casey D.E. Polypharmacy: combining antipsychotic medications in the treatment of schizophrenia. J. Pract. Psychiatry Behav. Health 7 (1999) 229-233
34. World Health Organisation. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines (1992), World Health Organisation, Geneva